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ABSTRACT 
Agins, Alan Paul. M.S., University of Rhode Island, 1980. 
Effects of Liquid Membranes on Gastrointestinal Absorption 
of Drugs in Rats. Major Professor: Dr. George C. Fuller. 
A liquid membrane system was investigated as a potential 
antidotal treatment for acute drug overdose. The effective-
ness of orally administered liquid membranes in simulated 
acute secobarbital, phencyclidine and strychnine poisoning 
was assessed in fasting rats. 
Four milliliters of a liquid membrane suspension was 
administered immediately following drug intubations. The 
effect of liquid membrane on gastrointestinal absorption of 
secobarbital and phencyclidine was determined by comparison 
of duration of action (sleeping time) and blood drug concen-
tration over time in drug controls and treated rats. The 
effect on phencyclidine absorption was also determined from 
the total amount of drug and metabolites excreted in the 
urine over twenty-four hours. The effectiveness of liquid 
membranes and activated charcoal for reducing strychnine 
absorption was assessed by acute toxicity experiments. 
Duration of action of phencyclidine was 22 percent 
longer in liquid membrane treated rats while no significant 
difference existed between groups in secobarbital sleeping 
times. 
iii 
Blood level versus time analysis revealed no differences 
in blood levels between control and treated groups in both 
secobarbital and phencyclidine experiments. No difference 
existed in the total recovery of phencyclidine in urine in 
control and treated groups. Liquid membranes failed to pro-
tect rats from strychnine induced toxicity, whereas activated 
charcoal completely inhibited the toxic effect. 
These studies show that liquid membranes are relatively 
ineffective in reducing drug absorption in vivo and that the 
system probably serves as a reservoir for sustained release 
of the drug as it passes through the gastrointestinal tract. 
The lack of in vivo efficacy may be attributed to an appre-
ciable reduction in liquid membrane stability in the 
presence of gastrointestinal constituents such as bile salts 
and pancreatic secretions. 
iv 
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INTRODUCTION 
Human poisoning involving drug ingestion is common in 
the United States. Recent statistics show the number of 
accidental deaths from drugs increased by over SO percent 
between 1968 and 1976 (National Clearinghouse, 1978). In 
addition, the number of non-fatal poisonings is estimated to 
exceed one million per year, or about one per 200 population 
(Goldstein et al., 1974). 
Traditionally, acute drug overdoses have been treated 
by a variety of methods including gastric lavage, emetics, 
adsorbants, forced diuresis, peritoneal or hemodialysis. 
Some of these methods have limited efficacy, require skilled 
manpower, can lead to further complications in the patient, 
and at the very least are extremely unpleasant. 
Frankenfeld and coworkers (1976) first proposed the use 
of liquid membranes as an adsorbant system for antidotal 
treatment of acute drug overdose. They suggested that liquid 
membranes off er a number of potential advantages over many 
of the current methods including ease of preparation and 
administration, minimal patient resistance, and the ability 
to incorporate a variety of trapping agents would make them 
useful for a broad spectrum of drugs. 
1 
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Although liquid membrane technology is still at an 
early stage, preliminary in vitro data indicate potentially 
good efficacy and the need for evaluation of in vivo per-
formance. 
The present study represents the first attempt to 
evaluate liquid membrane performance in trapping drugs in 
the gastrointestinal tract of laboratory animals. 
LITERATURE SURVEY 
Antidotal Treatment 
Antidotal procedures are based on two concepts: first, 
the intensity of all chemical-biological reactions is related 
to the dose, or more accurately to the concentration of the 
chemical at the effector site in the tissue and second, 
following administration of a chemical to a biological speci-
man, the concentration of the chemical within the tissues is 
dependent upon the ability of biological barriers to prevent 
its translocation and on the chemical properties of the com-
pound which permit or prevent its translocation in the 
tissue. In addition, since translocation is a time dependent 
process, it may be said that the intensity of all chemical-
biological reactions is time dependent (Loomis, 1978). 
The present modes of emergency treatment in acute drug 
overdose are thus aimed at reducing the effective concentra-
tion of the drug at the site where the interaction occurs, 
thereby reducing the intensity and duration of the toxic 
effect, Within this framework, there exist both specific 
and non~specific procedures directed at either decreasing 
the rate or amount 0£ drug absorption from the gastro-
intestinal tract, increasing the rate of elimination of the 
3 
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drug from the body, or increasing the threshold for toxicity 
by administration of a specific pharmacological antagonist. 
In the latter case, however, specific antidotes exist for 
relatively few drugs and therefore the major thrust of anti-
dotal treatment lies in non-specific methodologies and must 
be tailored to the individual and the situation (Levine, 
1978). 
In the case of orally ingested compounds, removal of 
the ·unabsorbed chemical from the gastrointestinal tract 
represents the most direct and widely employed procedure 
for preventing further absorption of the drug. Abdallah 
and Tye (1967) studied the effectiveness of emetic drugs 
and stomach lavage in dogs fed a barium meal. Their results 
indicated that emesis was superior to lavage and that apo-
morphine was the most effective emetic agent. This study 
also showed that recovery of barium meal was dependent on 
the interval of time between ingestion and initiation of the 
procedure. In addition, with respect to apomorphine induced 
emesis, it was found that the action of this agent was com-
pletely inhibited in animals treated with hypnotic doses of 
thiopental. The authors concluded that following ingestion 
of overdoses of sedative type drugs, the production of emesis 
by centrally acting emetic agents cannot be relied on. 
Furthermore, apomorphi,ne induced emes is can be quite severe 
and potentiate CNS depressant effects of sedative drugs 
(Arena, 1974). Syrup of Ipecac is generally considered a 
safer agent for the induction of emesis since it has a 
s 
direct action on the gastric mucosa and can be eliminated 
with the vomitus. The effectiveness of the agent, however, 
tends to be quite variable and often requires fifteen to 
thirty minutes before onset of action (Lawson and Proudfoot, 
1971). 
Gastric aspiration and lavage is a procedure that is 
controversial among physicians. Those who advocate use of 
the procedure contend that although the amount of drug 
recovered by this means is extremely variable, in some cases 
substantial amounts can be recovered with benefit to the 
patient (Matthew et al., 1966). Others contend that the 
lavage procedure, if improperly performed, can lead to aspi-
ration of lavage fluids, hasten gastric emptying into the 
intestine and in some cases, such as strychnine poisoning, 
the stimulation associated with intubation may precipitate 
convulsions (Meyers et al., 1976). 
Once actual removal of an ingested drug has been 
attempted or accomplished the use of adsorbants for further 
decontamination may be indicated. Activated charcoal has 
been advocated as an effective therapeutic agent in acute 
ingestions for many years (Holt and Holtz, 1963). In vitro 
studies (Decker et al., 1968) have shown that this agent is 
capable of adsorbing a wide variety of toxic materials from 
aqueous solutions, although there is considerable variability 
in amounts depending on the material. Gosselin and Smith 
(1966) have emphasized that adsorption is not the same as 
chemical destruction and that adsorption may be reversible, 
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leading to release of the offending chemical as the pH of 
the environment changes during passage through the gastro-
intestinal tract. Some in vivo studies, however, have shown 
activated charcoal to be effective. Fiser et al. (1971) 
reported that in dogs receiving barbiturates and glutethi-
mide, administration of activated charcoal one-half hour 
after drug intubation resulted in significantly decreased 
serum levels of the compounds and a concommitant reduction 
in CNS depression. In addition, the charcoal-drug complex 
appeared to be stable, in that no significant dissociation 
was demonstrated over the twenty-four hour monitored experi-
ments. Levy and Tsuchiya (1972) found that activated char-
coal was effective in reducing aspirin absorption in man. 
They reported, however, that the adsorption on activated 
charcoal was partially reversible and was probably due to the 
higher pH of intestinal fluids and the competitive effects of 
constituents of these fluids. Despite the increasingly fre-
quent recommendations in the literature that activated char-
coal be used as a gastrointestinal decontaminant, the sub-
stance is rarely employed due to the lack of demonstrated 
efficacy in life-threatening acute intoxications under con-
trolled conditions (Hayden and Comstock, 1975). 
A variety of other adsorbants including cholestyramine 
(Dordoni et al., 1973), Arizona montmorillonite and evaporated 
milk (Chin et ~·, 1969) and "universal antidot_e" (Picchioni 
et al., 1966) have been evaluated as alternatives to acti-
vated charcoal. Although these substances may be useful in 
7 
isolated cases? none appear to have the general applicability 
of activated charcoal. In the case of "universal antidote," 
it has been demonstrated that the combination of tannic acid 
and magnesi~~ oxide with activated charcoal interfers with 
the adsorbant activity of the charcoal and is hence less 
effective than activated charcoal alone (Picchioni et al., 
1966). 
Cathartics such as liquid petrolatum, sodium sulfate, 
and magnesium hydroxide have also been implicated for prevent-
ing absorption and hastening the transit of chemical through 
the intestine. However, information on the effectiveness of 
such procedures is lacking (Loomis, 1978). 
Liquid Membranes 
Liquid membranes were developed at Exxon Corporation 
(Li, 1968) as an industrial encapsulation process to solve 
a variety of separation problems. Since then, liquid mem-
branes have been implicated for several industrial applica-
tions including separation of hydrocarbons and the removal 
of organic contaminants such as phenol (Cahn and Li, 1974) 
6+ 2+ 2+ 
and toxic inorganic ion such as Cr . , Hg , and Cd . 
(Kitagawa et al., 1977) from wastewater. 
Liquid membranes aTe thin, spherical liquid shells which 
encapsulate microscopic droplets of one phase and separate 
these from a bulk external phase. Liquid membranes are 
formed by first making an emulsion of two immiscible phases 
and then dispersing the emulsion in a third phase (continuous 
8 
phase). The continuous phase and the encapsulated phase are 
generally miscible, but they are not miscible with the mem-
brane phase. There are presently three types of liquid mem-
brane systems (Appendix Table A) . One is a water-in-oil-in-
water emulsion, one is an oil-in-water-in-oil emulsion and 
the third is a gas-in-fluorocarbon-in-water system. The 
liquid membrane phase usually contains surfactants, additives, 
and a base material which is a solvent for the other ingre-
dients. The surfactants and additives are used to control 
the stability, permeability, and selectivity of the membrane. 
The encapsulated phase can be formed into a "sink" for trap-
ping certain agents, or as a reservoir for releasing sub-
stances into the external phase. 
In recent years, interest has been focused on the poten-
tial application of liquid membranes in the biomedical and 
biochemical fields. A n~~ber of areas of research have been 
implicated including the encapsulation of enzyme processes, 
the sustained, slow release of compounds, oxygenation of 
blood, and removal of toxic substances from the human body. 
In the encapsulation of enzymes, liquid membranes may 
act to immobilize or protect enzymes from deactivating sub -
stances and non-optimal environments while maintaining free 
access to the desired substrate. In addition, preparations 
may allow for the encapsulation of necessary cofactors and 
optimal reaction conditions. May and Li (1974) encapsulated 
purified phenolase and dispersed the liquid membrane in an 
external aqueous phase containing phenol. Their results 
9 
showed that phenol successfully diffused through the mem-
brane, contacted the enzyme and was converted to oxidation 
products which accumulated in the internal phase. Another 
facet to enzyme encapsulation involves the delivery of 
specific enzymes to the intestinal tract. The liquid mem-
branes would serve both to protect the enzyme from gastric 
degradation and as a reservoir for sustained release under 
physiological conditions. 
Liquid membrane technology has also been extended to 
the area of blood oxygenatin. Conventional oxygenator 
devices, although efficient, eventually lead to damage of 
blood proteins and cells. Wallace et al., 1975) have found 
that oxygen encapsulated by certain fluorocarbons forms the 
basis for an excellent oxygenation device which circumvents 
many of these difficulties. They suggest that fluorocarbons 
are particularly suited for liquid membrane material due to 
the high solubility of oxygen and carbon dioxide and the 
good compatability with blood. Experiments, in vitro and in 
dogs, have shown that the system is capable of replenishing 
oxygen and removing carbon dioxide from blood with no indi-
cation of damage to cells or other constituents. 
The removal of toxic substances from the human body 
represents an interesting potential for liquid membranes. 
Research has been divided into two areas: the treatment of 
chronic uremia and the emergency treatment of acute drug 
overdose. 
J- .; 
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Asher and coworkers (1974, 1976, 1977, 1978) have been 
developing a liquid membrane system that would serve as 
adjunct treatment to dialysis in chronic uremia. The system 
involves the use of two liquid membrane formulations for the 
removal of one of the uremic toxins, urea. In principle, 
urea diffuses from the blood into the intestine and is hydro-
lyzed into ammonia and carbon dioxide by the enzyme urease 
present in the intestinal lumen. In the presence of one of 
the liquid membrane formulations, containing an encapsulated 
organic acid, the lipid soluble. ammonia species permeates the 
oil phase of the membrane, reacts with the encapsulated acid 
and becomes trapped in the form of an oil-insoluble ammonium 
ion. In addition, a liquid membrane formulation containing 
the enzyme urease would be given simultaneously. Since the 
levels of urease in the intestine are governed by the level 
of proteolytic activity of pancreatic secretions, the hydrol-
ysis of urea may become rate limiting. Asher et al. (1977) 
have demonstrated a controlled release of the encapsulated 
phase of liquid membranes moderated by the levels of bile 
and pancreatin. They predicted that a higher concentration 
of pancreatic secretions, resulting in an increased rate of 
urease inactivation, would be balanced by a greater rate of 
release of the encapsulated enzyme to maintain activity in 
the small intestine. The instability of liquid membranes 
under physiological conditions, while advantageous in some 
circumstances, represents a problem with respect to those 
liquid membranes designed to trap toxins. To date, in vitro 
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studies have been utilized primarily to identify proper 
formulations and suspending techniques necessary for obtain-
ing biological stability. In addition, liquid membranes 
have been administered via cannulae to the small intestine 
of surgically azotemic dogs (Asher et al., 1979). Results 
indicate good mucosal tolerance to liquid membranes and sub-
stantial reduction of urea as measured by decreases in BUN 
levels. 
The application of liquid membrane technology to acute 
drug overdose was first proposed by Frankenfeld and coworkers 
(1976). The principle involved in drug transport in liquid 
membranes is demonstrated in Appendix Figure A. The example 
is for an acidic drug such as secobarbital and a liquid mem-
brane containing a basic pH buffer as the encapsulated phase. 
Drug transfer from the external aqueous phase follows the 
same principle governing passive diffusion of drugs through 
biological membranes, The unionized drug~ having appreciable 
oil solubility, permeates the liquid membrane, diffuses in 
the direction of the concentration gradient and becomes 
ionized at the high pH of the central aqueous phase. A mem-
brane made from hydrocarbon oil is virtually impenetrable to 
ions due to its low dielectric constant and hence the drug 
is trapped in the form of an oil-insoluble anion. The 
opposite situation would exist for basic compounds such as 
phencyclidine or the alkaloid, strychnine. The internal 
phase would consist of an acidic pH buffer and the drug would 
be trapped in the form of an oil-insoluble cation. 
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In addition to ion-trapping, the internal aqueous 
phase can be formulated into a high capacity sink using 
plasma proteins, activated charcoal, or specific drug anti-
bodies that bind tenaciously to drug. 
In principle, ingested liquid membranes would pass 
through the gastrointestinal tract, trap and unabsorbed 
drug present in the lumen and be eliminated via the bowel. 
The effectiveness of liquid membranes has been studied 
in vitro. Frankenfeld and coworkers (1976) have shown that 
under the most favorable conditions, liquid membranes are 
capable of rapid uptake of model drugs. Up to 95 percent 
of both phenobarbital and aspirin can be removed from donor 
solutions in five minutes or less of contacting time. Chaing 
et al. (1978) extended these studies to a number of other 
barbiturates. All the barbiturates, with the exception of 
barbital, were extracted more rapidly than phenobarbital 
(Appendix Table B). Most recently, Chilamkurti (1979) and 
Yang (1979) have studied the sophisticated kinetics involved 
in transfer of drug ·through liquid membranes. These studies, 
in addition to delineating the basic mechanisms governing 
solute transport, have identified some of the critical fac-
tors imparting efficacy to the system such as the diameter 
of the internal microdroplets, the viscosity of the oil 
phase, the strength of the encapsulated pH buffer, and 
chemical properties of the drug. 
EXPERIMENTAL 
Animals 
Male Sprague-Dawley rats, weighing 250-300 grams, were 
purchased from Charles River Breeding Laboratories, Inc. 
(Wilmington, MA). The rats were housed in groups of six in 
colony cages at an ambient temperature of 24-27°C with 
alternating twelve hour light/dark cycles. Rats were fed 
Purina Laboratory Chow and water ad libitium. Rats were 
fasted twenty-four hours prior to experiments. 
Materials 
Secobarbital and Seconal sodium were obtained from Eli 
Lilly & Company (Indianapolis, IN). Hexobarbital was 
obtained from K & K Laboratories, Inc. (Plainview, NY). 
Strychnine sulfate was obtained from Mallinckrodt Chemical 
Works (St. Louis, MO). Ketamine hydrochloride (KetasetR) 
was obtained from Bristol Laboratories (Syracuse, NY). Acti-
vated charcoal was obtained from Sigma Chemical Company (St. 
Louis, MO). Phencyclidine hydrochloride was kindly donated 
by Dr. Robert E. Willette, National Institute of Drug Abuse, 
Rockville, MD. Ail other reagents used were anlaytical 
grade. 
13 
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Liquid Membrane Formulations 
Liquid membrane forming emulsions, Codes S73 - 3l(R) and 
S73-118-2 were supplied by Exxon Research and Engineering 
Company, Linden, NJ. The oil phase of both is composed of 
a combination of an isoparaffinic mineral oil (Isopar MR) 
and a white mineral oil (Markol 87R). A high molecular 
weight polyamine is present in the oil phase as a strength-
ening agent. The internal aqueous phase of S73-3l(R) is a 
pH 10 buffer consisting of boric acid, KCl and NaOH. The 
internal aqueous phase of S73-118-2 is a pH 2 buffer made of 
HCl and KCl. The ratio of oil phase to aqueous phase is 1:1 
(Frankenfeld, 1979). 
Liquid Membra~e Suspensions 
To a 2SO ml beaker are added SO mls distilled water, 
0.S g methylcellulose (4000cps), 0.2 g NaHC0 3 , and 0.2S g 
NaCl. The contents are mixed at approximately 1200 RPM for 
1 minute using a variable speed mixer fitted with a one and 
one-half inch propeller. The mixing is reduced to approxi-
mately 400 RPM and SO mls of the liquid membrane forming 
emulsion is added. After 30 seconds, the mixing is reduced 
to approximately 100 RPM and maintained for the duration of 
the experiment. Aliquots for intubation are drawn from the 
beaker with a S ml plastic syringe fitted with a 16 gauge 
oral intubation tube. 
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Procedures 
Groups of rats received either secobarbital or phen-
cyclidine by oral intubation. Drug solutions were made in 
water such that 0.1 ml was administered per 100 g of body 
weight. Half the rats in each experiment received 4 mls 
of the appropriate liquid membrane suspension, while the 
remaining rats received 4 mls of water immediately after 
drug intubation. 
In sleeping time experiments, time of drug intubation 
(T0 ) was recorded for each animal. The time from drug in-
tubation to the loss of righting response was recorded as 
latency (T1 ). At the onset of anesthesia, all animals were 
placed on their right sides. Sleeping time was measured as 
the duration of time from loss of righting response until 
the animal regained ·this response (Tp-T1). 
In blood level experiments, blood samples (approx. 0.5 
mls) were drawn from each rat by cardiac puncture at 30 min, 
1, 2, and 3 hours post intubation. Blood samples were imme-
diately transfe·rred to glass t;est tubes containing 0. 02 mls 
of a 3.75% EDTA solution as anticoagulant. Tubes were kept 
on ice until all samples had been collected. 
St~_ychnine Acute Toxicity 
Rats were divided into three groups. Each group 
received a dose of ~trychnine approximately one and one-half 
times the oral LD 50 (Barnes and Eltherington, 1965). Imme-
diately following drug intubation, one group received 4 mls 
' 
16 
of a 35 mg/ml solution of activated charcoal in water. 
Time of drug intubation was recorded and all animals were 
maintained in an environment of minimal external stimuli. 
The ntnnber of deaths and the latency to death were recorded. 
Non-lethals were monitored for twenty-four hours post 
intubation. 
Determination of Blood Secobarbital 
Quantitation of secobarbital in the 'blood is determined 
gas chromatographically. Extraction of drug from blood is 
based on the procedure of Dvorchik (1975). Two hundred 
microliters of whole blood are placed in a glass test tube. 
Twenty microliters of a 300 µg/ml hexobarbital in acetone 
solution is added to each tube as an internal standard. Two 
mls of chloroform is then added and the tubes are vortexed 
for one minute followed by centrifugation at 500 RPM for five 
minutes. The chloroform phase is removed and transferred to 
clean 15 ml conical centrifuge tubes. The chloroform is 
evaporated to dryness at room temperature under nitrogen. 
The walls of the tubes are then rinsed with 50 µl chloroform 
and again evaporated to dryness . Secobarbital standards, 
ranging from 10 to 50 µg/ml a r e prepared by adding a known 
volume of a secobarbital in acetone · solution to glass tubes 
and evaporating to dryness under a stream of nitrogen. Two 
hundred microliters of fresh blood is added to each tube and 
the contents mixed by gentle shaking. Standards are then 
extracted along with the blood samples as above. 
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Prior to analysis, the tubes containing drug residue 
are reconstituted with 25 µl of chloroform. Approximately 
2 µl of the chloroform extract are injected into a Packard 
model 804 gas chromatograph equipped with a flame-ionization 
detector. The column is a 3 foot X 1/8 inch diameter glass 
column containing 3% OV-1 on Gas Chrom Q 100/120. The 
column is preconditioned for 24 hours at 220°C and a nitro-
gen flow rate of about 15 ml/min. The operating conditions 
are: injection port and detector--250°C, oven--190°C, air 
flow rate--300 ml/min, hydrogen flow rate--30 ml/min and 
nitrogen flow rate--35 ml/min. Sensitivity is set at l0- 11 , 
with an attenuation of 64. 
Quantitation is accomplished by obtaining a ratio of 
secobarbital peak height to hexobarbital peak height and 
comparing values to those obtained from the secobarbital 
standards. 
Determination of Blood Phencyclidine 
Quantitation of phencyclidine in blood specimens is 
based on the gas-chromatographic procedure of Reynolds 
(1976). The extraction procedure, using n-butyl chloride, 
is modified for smaller blood samples by ratioing extraction 
components. To glass test tubes is added O.~ mls of whole 
blood. Fifty microliters of a 100 µg/ml aqueous ketamine 
HCl solution are added to each tube as an internal standard. 
The contents are mixed briefly and are then made alkaline 
with two drops of 50% NH40H. Two mls of n ~ butyl chloride 
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are added and the tubes are vortexed for 2 minutes, then 
centrifuged at 500 RPM for 5 minutes. The top, or n-butyl 
chloride layer, is pipetted into a clean test ·tube and back 
extracted with 1.0 ml of 0.5 N HCl for 1 minute by vortexing. 
The layers are again separated by centrifugation and the 
n-butyl chloride layer is pipetted off and discarded. The 
HCl layer is aerated for 2 minutes to remove all residual 
n-butyl chloride. The HCl is made strongly alkaline with 
2 drops of 10 N NaOH and reextracted with 1.0 ml of chloro-
form for 1 minute. The chloroform layer is transferred to 
clean 5 ml screw cap vials and evaporated to dryness at room 
temperature under nitrogen. 
A series of standards ranging from 2.5 to 20 µg/ml are 
prepared in drug free blood by the addition of known volumes 
of an aqueous phencyclidine solution. Standards are extracted 
along with the blood samples as described above. 
The vials containing drug residue are reconstituted 
with 20 µl of chloroform and approximately 2 µl are injected 
onto the OV-1 column as described previously. The operating 
parameters are as follows: injection port--200°C, oven--
1800C, detector--225°C, air flow rate--300 ml/min, hydrogen 
flow rate--30 ml/min and nitrogen flow rate--40 ml/min. 
Sensitivity is set at 10- 11 with attenuation 32. Quantita -
tion is accomplished by comparison of peak height ratios of 
phencyclidine to ketamine in the unknown samples and the 
standards. 
'rl 
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Recovery of Phencyclidine in Urine 
Groups of rats received either phencyclidine and water 
or phencyclidine and liquid membrane suspension. Immediately 
following intubations animals were placed in separate meta-
bolic cages. Urine was collected over a 24 hour period 
after which urine volumes were recorded and samples analyzed 
for drug content. 
Quantitation of unchanged phencyclidine and metabolites 
in urine is determined as follows: 2.0 mls of urine are 
pipetted into lS ml round bottom screw-cap test tubes and 
subjected to mild hydrolysis by the addition of 0.3 mls of 
6 N HCl and incubation in a 60°C water bath with gentle agi-
tation for 30 minutes. When hydrolysis is completed, tubes 
are allowed to reach room temperature and then urine is made 
alkaline by addition of concentrated NH40H. To each tube 
are added SO µl of a 2 mg/ml aqueous ketamine solution as 
internal standard and 8.0 mls of chloroform. The tubes are 
placed on a platform shaker, extracted for 10 minutes and 
then centrifuged at SOO RPM for S minutes. The urine is 
removed and discarded. The chloroform layer is filtered 
th:rough Wha tman no. S41 filter paper containing sodium sul-
fate into lS ml screw-cap vials and evaporated to dryness 
at room temperature under nitrogen. Standards ranging from 
SO to 200 µg/ml are prepared in drug free urine and ex-
tracted as above. 
The drug residue is reconstituted with SO µl of chloro-
form and between 1 and 2 µl are injected onto the OV-1 
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column. All operating parameters are the same as described 
in the phencyclidine blood level determination section. 
S . . . 10- 10 . h . 32 ens1t1v1ty was wit attenuation . Quantitation of 
unchanged phencyclidine was accomplished using the method 
of peak height ratios as before, while quantitation of 
metabolites was accomplished by ratioing peak areas of 
metabolites to peak area of ketamine. 
Statistical Methods 
Students' t-test was used to test for significant dif-
ferences between sample means. The sample means, standard 
errors of the means and t-statistics were calculated on an 
Olivetti-Underwood Programma 101 computer using the follow-
ing formulae. 
a) Arithmetic means of sample: 
b) Estimated standard error of the mean: 
c) t-statistic: 
Acceptable level of significance in these studies was defined 
as p < 0.05 for a two-tailed t-test. 
RESULTS 
Administration of four milliliters of liquid membrane 
suspension to control rats resulted in no overt effects and 
demonstrated that the animals could easily tolerate the 
volume of material. Rats remained normal and active. Stools 
from treated animals were greasy and soft and coated with a 
milky white, oily film. 
Sleeping Time Experiments 
Secobarbital at a dose of 100 mg/kg, produced anesthe-
sia in all rats in both drug control and liquid membrane 
treated groups. The mean latency to loss of righting 
response was the same in both groups. Mean sleeping time 
did not differ significantly between the two groups, how-
ever, the liquid membrane treated group showed approximately 
three times the variability of drug control (Table I). 
Phencyclidine, at a dose of 50 mg/kg, produced extreme 
ataxia and stereotypic behavior in all rats within five 
minutes after intubation. The latency to loss of righting 
response was not significantly different between drug control 
and liquid membrane treated groups. All rats in both groups 
displayed mild clon~s intermittently throughout the 
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TABLE I 
Effect of Liquid Membrane Administration 
on Secobarbital Sleeping Time in Ratsa 
Treatment 
Secobarbital 
+ 
water 
Secobarbital 
+ 
liquid membrane 
s 
s 
Latency to 
loss of 
righting response 
min c 
6.6 ± 1.2 
6.6 ° 1.6 
Sleeping time 
(min) c 
252.6 ° 11.4 
321.0 ° 32.S 
aSeconal sodium in water as a dose of 100 mg/kg was admin-
istered by oral intubation; rats received drug plus 4 mls 
liquid membrane suspension Code 573-3l(R); controls 
received drug plus 4 mls water. 
b N represents the number of rats in each group. 
c Values are mean ± S.E.M. 
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experiment. Mean sleeping time was 22% longer (p < 0.05) 
in the liquid membrane treated group (Table II). 
Blood Level Experiments 
Under the GLC conditions described earlier, the seco-
barbital peak appears at 1.3 minutes and the hexobarbital 
internal standard peak at 1.7 minutes from the time of injec-
tion. An example of a chromatogram is shown in Figure I. 
The standard curve was linear throughout the range of con-
centrations tested. 
The peak blood concentration of secobarbital for both 
the drug control and liquid membrane treated groups was 
observed at 30 minutes post intubation and levels declined 
over the next 2-1/2 hours (Figure II). There were no sig-
nificant differences in mean blood levels between the two 
groups at all times analyzed. Analysis of area under the 
blood concentration versus time curves showed that bio-
availabili ty of drug was within 3% for the two groups 
(Table III). 
An example of a chromatogram for phencyclidine analysis 
is shown in Figure III. Under the described GLC conditions, 
the Ketamine internal standard peak appears at 2.0 minutes 
and the phencyclidine peak at 2.5 minutes after injection. 
The standard curve was linear throughout the range of con-
centrations tested and passed through the origin. Figure IV 
shows the blood concentration versus time curve for drug 
control and liquid membrane treated groups. Blood levels 
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TABLE II 
Effect of Liquid Membrane Administration 
on Phencyclidine Sleeping Time i n Ratsa 
Treatment 
l'hencycl idine 
+ 
water 
Phencyclidine 
+ 
liquid membrane 
5 
5 
Latency to 
loss of 
righting resonse 
(min) c 
12.6 ± 1.8 
11.0 ± 1.0 
Sleeping time 
(min) 
108.2 ± 6.4 
139.4 ± 10.3d 
aPhencyclidine hydrochloride in water at a dose of 50 mg/kg 
was administered by oral intubation; rats received drug 
plus 4 mls liquid membrane suspension Code 573-118-2; con-
trols received drug plus 4 mls water. 
bN represents the number of rats in each group. 
cValues are mean ± S.E.M. 
d p < 0 . 05 vs. control. 
100 
o\O 
0 
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FIGURE I 
Gas Chromatogram for the Analysis of 
Secobarbital Levels in Rat Blooda,b 
SECOBARBITAL 
HEXOBARBITAL 
0 2 3 
TIME (Min) 
4 
aObtained from the injection of two microliters of a 
chloroform extract from 0.2 mls whole blood. 
b Column was a 3' X 1/8" glass column containigg 3% OV-1 
on Gas Chrom Q 100/120; Oven temperature-190 , 
10 
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FIGURE i1 
Effest of Liquid Membrane Administration on Blood 
Levels of Secobarbital in Ratsa 
b •-SECOBARBIT AL 4-
WATER 
C1•SECOBARBIT AL+ 
LIQUID MEMBRANE 
0--------------------------------------------
0 2 3 
TIME lhours l 
aSeconal sodium in water at a dose of 100 mg/kg was 
administered by oral intubation; rats received drug 
plus 4 mls of either liquid membrahe suspension 
(Code 573-31R) or water. 
bp . oints represent mean + S.E.M, for 6 rats. 
TABLE II I 
Summary of the Effects of Liquid Membrane Administration 
on Secobarbital Bioavailability Parameters in Ratsa 
Treatment 
Secobarbital 
+ 
water 
Secobarbital 
+ 
liquid 
membrane 
Nb 
5 
5 
Time of peak 
concentration 
(min) 
30 
30 
Peak blood 
. c 
concentration 
(µg/ml) 
42.8 ± 3.2 
34.2 ± 4.3 
Area under 
the blood cone. 
vs. time curved 
(µg/ml x hrs.) 
69.6 
67.4 
aSeconal sodium in water at a dose of 100 mg/kg was administered by oral intubation; 
rats received drug plus 4 mls liquid membrane suspension Code 573-31(R); controls 
received drug plus 4 mls water. 
bN represents the number of rats in each group. 
c Values represent mean ± S.E.M. 
dCalculated from 0-3 hours by trapezoidal rule using mean blood concentration values. 
N 
'-1 
100 
o\O 
0 
0-
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FIGURE III 
Gas Chromatogram for the Analysis ofb 
Phencyclidine Levels in Rat Blooda, 
-CHC1 3 
KETAMINE 
PHENCYCLIDINE 
l 3 4 
TIME lmin) 
5 
aObtained from the inje~tion of two microliters of a 
.chloroform extract from 0.5 mls whole blood. 
bColumn was a 3 1 X 1/8" glass column containing 3% OV--1 
. 0 
om Gas Chrom Q 100/120; Oven temperature-180 . 
z 
0 
H 
E-< 
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FIGURE IV 
Effect of Liquid Membrane Administration on Blood 
Levels of Phencyclidine in Ratsa 
b •-PHENCYCLJDINE + 
WATER 
o -PHENCYCLJDINE + 
LIQUID MEMBRANE 
Q-t------------------------------------------
· a 2 
TIME (_hours l 
aPhencyclidine hydrochloride in water at a dose of 
SO mg/kg was administered by oral intubation; rats 
received drug plus 4 mls liquid membrane suspension 
lCode 573-118-2) or water, 
b . Points represent mean~ S,E.M. for 5 rats. 
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appeared to peak at one hour after intubation and rapidly 
declined over the following two hours . The liquid membrane 
treated group showed peak blood levels of drug at 30 minutes 
followed by a less rapid decline in levels over the next 
2-1/2 hours. No statistically significant differences in 
blood levels existed owing in part to the exterme varia-
b i lity in the liquid membrane treated group. Area under the 
curve calculations revealed a 14% increase in bioavailability 
of phencyclidine in the liquid membrane treated group (Table 
IV). 
Recovery of Phencyclidine in Urine 
Analysis of urine revealed the presence of three major 
metabolites in addition to unchanged phencyclidine (Figure 
V). Total recovery of phencyclidine over twenty-four hours 
was calculated by summation of the total amount of metab-
olites and unchanged drug multiplied by the volume of urine 
collected ·for eich rat. The mean recoveries for the drug 
control and liquid membrane treated g~oups were not signifi-
cantly different. There appeared to be a slight difference 
in the distribution of unchanged drug and metabolites within 
the two groups, with liquid membrane treated group showing 
a higher mean recovery of unchanged phencyclidine and a 
lower mean recovery of metabol i tes as compared to the drug 
control group. These differences were not statistically 
significant (Table V). 
·-~'~ ,. .. ,.~~· 
TABLE IV 
Swnmary of the Effects of Liquid Membrane Administration 
on Phencyclidine Bioavailability Parameters in Ratsa 
Treatment 
Phencyclidine 
+ 
water 
Phencyclidine 
+ 
liquid membrane 
Nb 
s 
s 
Time of peak 
concentration 
(min) 
60 
30 
Peak blood 
concentrationc 
(µg/ml) 
4.9 ± 0.40 
4.4 ± 0.76 
Area under 
the blood cone. 
vs. time curved 
(µg/ml x hrs) 
7.9 
9.2 
aPhencyclidine hydrochloride in water at a dose of SO mg/kg was administered by 
oral intubation; rats received drug plus 4 mls liquid membrane suspension Code 
573-118-2; controls received drug plus 4 mls water. 
bN represents the nwnber of rats in each group. 
cValues represent mean ± S.E.M. 
dCalculated from 0-3 hours by trapexoidal rule using mean blood concentration 
values. 
VI 
....... 
IOQ 
o\<> 
o. 
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FIGURE V 
Gas Chromatogram for the Analysis of 
Phencyclidine and Metagolites 
in Rat Urinea, ,c 
-CHC1 3 
. A Ketamine Phencyclidine 
c 
I. 2 
TIME (min) · 
4 
aObtained from the injection of two microliters of a 
chloroform extract from 2 ml£ urine. 
b Column was a 3 1 X 1/8" glass column containing 3% OV-1 
on Gas Chrom Q 100/120; Oven temperature-180°. 
cRetention time of metabolites are: A-0.51 min., B-1 .2 
min., C-3.0 min. 
Treatment 
Phencyclidine 
+ 
water 
Phencyclidine 
+ 
liquid membrane 
TABLE V 
Effect of Liquid Membrane Administration on 
Recovery of Phencyclidine in Rat Urinea 
Nb 
5 
5 
Amount of 
unchanged 
phencycli~ine 
(mgs) 
1.06 ± 0.16 
1.27 ± 0.20 
Amount of 
metabolides 
(mgs) 
0.61 ± 0.17 
0. 36 ± 0. 0 5 
Total 
recoverlc 
(mgs) 
1.67 ± 0.11 
1.62 ± 0.21 
aPhencyclidine hydrochloride in water at a dose of 25 mg/kg was administered by 
oral intubation; rats received drug plus 4 mls liquid membrane suspension Code 
573-118-2; controls received drug plus 4 mls water. 
bN represents the number of rats in each group. 
cTotal recovery of phencyclidine and metabolites in urine collected for 24 hours 
after drug intubation. 
d Values are mean ± S.E.M. 
VI 
0-1 
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Strychnine Acute Toxicity 
Administration of strychnine, at a dose of 25 mg/kg, 
resulted in 100% lethality rate in control rats. The mean 
latency to death was 14.6 minutes. Rats receiving activated 
charcoal immediately following strychnine intubation re-
mained alive and active with no signs of toxicity. Twenty-
· four hours after intubations, rats were alive and exhibited 
no signs of latent toxicity. Rats receiving liquid membrane 
following strychnine intubation were all dead within 13 
minutes with a mean latency of 9.2 minutes (Table VI). 
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TABLE VI 
Comparison of the Effectiveness of Liquid Membrane and 
Activated Charcoal Administration in Preventing 
Strychnine Toxicity in Ratsa 
Treatment 
Strychnine 
+ 
water 
Strychnine 
+ 
activated 
charcoal 
Strychnine 
+ 
liquid membrane 
5 
5 
5 
Number 
dead 
5 
0 
5 
Latency 
to death 
(min) c 
14.6 ± 2.1 
9.2 ± 1.4 
aStrychnine sulfate in water at a dose of 25 mg/kg was 
administered by oral intubation; rats received either 
4 mls liquid membrane suspension Code 573-118-2 or 4 mls 
of a 35 mg/ml solution of activated charcoal; controls 
received drug plus 4 mls water. 
bN represents the number of rats in each group. 
cValues are mean ± S.E.M. 
DISCUSSION 
Sleeping time is a frequently employed test for the 
evaluation of parameters which affect the pharmacological 
activity of the agent producing the anesthesia. Since the 
intensity and duration of a pharmacological effect is pro-
portional to the concentration of drug at an effector site, 
any alteration~ in the absorption, metabolism or excretion 
of anesthesia producing drug will alter the duration of 
action. Many studies have been focused on alterations in 
sleeping time . as a function of biological differences (Quinn 
et al., 1958) or chemical interactions that affect barbi-
turate metabo~ism (Axelrod et al., 1954). These studies 
have shown that there is a direct relationship between dura-
tion of action (sleeping time) and the plasma and brain 
tissue levels of drug. Sleeping time experiments have also 
been extended to studies involving alteration in gastro-
intestinal absorption of anesthesia producing agents. 
Recently, Picchioni and Consroe (1979) have studied the 
effect of activated charcoal on phencyclidine toxicity. 
Their results showed a significant reduction in duration of 
anesthesia in dogs as a result of activated charcoal treat-
ment. 
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Sleeping time experiments in the present study were 
~hus based on the principle that a reduction in the amount 
of drug available for gastrointestinal absorption due to 
liquid membrane will result in a concommitant decrease in 
blood and brain levels of drug and therefore a reduction 
in the duration of action of the drug. 
In both the secobarbital and phencyclidine experiments, 
there are no differences in the latency to loss of righting 
response for drug control and liquid membrane treated groups. 
These data suggest that the rate of absorption from the 
gastrointestinal tract is not altered by the presence of the 
liquid membrane and, that the amount of drug available for 
absorption is sufficient to produce anesthesia. In contrast, 
liquid membranes do alter sleeping time duration in phen-
cyclidine treated rats. The group receiving liquid membrane 
showed a 22% increase in mean sleeping time. These findings 
suggest that the blood levels of drug necessary to sustain 
anesthesia are being maintained for a longer period of time 
in liquid membrane treated animals. This interpretation is 
supported by blood level experiments. 
Although no significant differences exist in mean blood 
levels between drug control and liquid membrane treated 
groups over the course of the experiments, a similar trend 
is apparent in both secobarbital and phencyclidine experi-
ments. Mean peak blood levels in liquid membrane treated 
groups appear slightly lower than in drug controls, suggest-
ing that a small portion of the original dose may be trapped 
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by liquid membranes. However, between the first and second 
hour after drug intubation there is an apparent leveling 
in the slope of the elimination portion of the blood con-
centration versus time curve. This finding tends to corre-
late well with the effect seen in sleeping time experiments 
and suggests that although liquid membranes may be trapping 
small quantities of drug initially, the effect is reversible 
and the liquid membrane may be serving as a reservoir for 
sustained release of drug as it passes through the gastro-
intestinal tract. 
This suggestion is supported by comparison of drug bio-
availabili ty as measured by area under the blood concentra-
tion versus time curve. In the secobarbital experiment, 
there was less than a 3% difference in the areas under the 
curve for drug control and liquid membrane treated animals 
indicating that the amount of drug absorbed over the three 
hour sampling period was equal in both groups. In the 
phencyclidine experiment, the liquid membrane treated group 
showed a 14% increase in drug bioavailability over controls. 
This finding suggests that liquid membrane may enhance the 
absorption of the basic drug by translocating it further 
through the intestine to a more favorable alkaline environ-
ment. 
Total twenty-four hour recovery of phencyclidine in 
the urine did not differ between drug control and liquid 
membrane treated groups. This finding further indicates 
that liquid membrane does not irreversibly trap significant 
amounts of the original drug dose. 
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A comparison of the effectiveness of liquid membrane 
and activated charcoal for preventing strychnine toxicity 
revealed that administration of activated charcoal pro-
tected all animals against toxicity. This served as a posi-
tive control. Liquid membrane not only was incapable of 
preventing toxicity, but appeared to decrease the r latency 
to death when compared to drug controls. This further 
supports the concept that the liquid membranes may be in-
creasing the rate of translocation of the basic compound, 
strychnine, into the more alkaline intestinal environment. 
The proven efficacy of liquid membranes in vitro does 
not appear to carry over to the in vivo situation. The 
inability of liquid membranes to trap and remove drug from 
the gastrointestinal tract indicates that under physiological 
conditions, factors exist that may compromise the perform-
ance of liquid membranes. Since the principle underlying 
liquid membrane function requires that the encapsulated 
aqueous phase remains encapsulated, rupturing of liquid mem-
branes would result in leakage of the internal pH sink and 
a concommitant decrease in the trapping capacity of the 
system. Rupture occurring after drug has been trapped would 
result in returning the drug to the externa~ phase (intes-
tinal lumen), making it available once again for absorption. 
The leakage effect has been demonstrated in vitro. 
Chiang et al. (1978) showed that in the presence of bile 
salts, liquid membrane uptake of pentobarbital ceased after 
ten minutes, followed by increasing drug concentration in 
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the donor solution during the next two hours of mixing. 
Similar results have been shown by Asher and coworkers 
(1977). In an in vitro system, liquid membranes leaked 
more than 35% of the encapsulated aqueous phase over a two 
hour period when contacted with a solution containing bile 
and pancreatin. These findings indicated that although 
liquid membranes are composed of non-digestible mineral 
oils, they are nonetheless subject to the emulsification 
action of bile salts. The effect of pancreatin on liquid 
membrane stability has been attributed to the solid content 
of the crude extract and not the enzymatic activity (Asher 
et al., 1976). 
In addition to the problem of leakage in liquid mem-
branes, another factor governing performance is the main-
tenance of the dispersion of liquid membrane capsules. 
suspending techniques are designed to generate many small 
diameter droplets, hence creating a large external surface 
area for rapid solute transfer. If the dispersed emulsion 
droplets coalesce with each other forming new, larger drop-
lets with diameters much over 2 mm, the reduction in surface 
area becomes limiting for rapid transfer. After oral 
administration, the minimal agitation occurring in the form 
of gastrointestinal motility may not be sufficient to main-
tain the original dispersion for extended periods of time. 
Asher and coworkers (1976) have shown that in addition to 
promoting leakage, bile and pancreatin promote extreme and 
rapid coalescence of liquid membrane droplets in vitro. 
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The addition of methylcellulose to the suspending solution 
appeared to reduce both the amount of leakage and coalescence 
when liquid membranes were contacted with bile and pancreatin. 
This phenomenon wa? attributed to the methylcellulose coat-
ing the surface of the droplets and rendering it resistant 
to bile. Further study indicated, however, that the methyl-
cellulose coating could be competitively replaced by protein 
such as albumin and that this led to loss of resistance. 
Another factor which may affect the characteristics of 
liquid membranes in vivo has been demonstrated by Yang (1979). 
It was shown that liquid membranes, encapsulating a concen-
trated pH buffer, are capable of absorbing or losing water 
when dispersed in solutions hypotonic or hypertonic relative 
to the internal aqueous phase. This finding implies that 
variations in osmolality along the gastrointestinal tract may 
alter the properties of liquid membranes. The effects caused 
by water absorption or loss have not been studied; however it 
is likely that this process would not only alter the nature · 
of the internal pH buffer, but may lead to structural changes 
compromising liquid membrane stability. 
In view of the data, of inadequate liquid membrane 
stability in in vitro systems simulating physiological con-
ditions of the gastrointestinal tract, the lack of effective-
ness of the liquid membrane formulations in the present in 
vivo study ca-n be attributed to the inability of the mem-
branes to remain in a stable, intact configuration once 
inside the animal, 
CONCLUSIONS 
(1) The liquid membrane formulations used in the 
present study did not effectively decrease the amount of 
drug reaching systemic circulation as measured by sleeping 
time, blood level, urine recovery and acute toxicity experi-
ments. These data confirm previous in vitro findings that 
a substantial reduction in liquid membrane stability occurs 
in the presence of gastrointestinal constituents such as 
bile and pancreatin. The effect of liquid membrane in pro-
longing the duration of action of phencyclidine, as well as 
increasing this drug's bioavailability over controls lends 
support to the potential use of liquid membranes as sustained 
release devices. 
(2) The use of liquid membranes to trap and remove 
toxins from the gastrointestinal tract has theoretical merit. 
A more biologically stable liquid membrane formulation, sub-
ject to less rupture and coalescence would be necessary for 
future in vivo testing. 
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TABLE A 
Some of the Demonstrated Liquid Membrane Systems 
Encapsulated Liquid Membrane Continuous Potential 
Phase Phase Phase Use 
Aqueous Oil Aqueous Chronic Uremia/ 
Drug Overdose 
Oil Aqueous Oil Hydrocarbon 
Separation 
Gas Fluorocarbon Aqueous Blood Oxygenation 
FIGURE A 
Schematic Diagram of Liquid Membrane System for Drug Removal 
Trapping Agent 
(pH 10 buffe1'::: / ( ~ 
Liqu i d Membrane 
(oil phase) 
Unionized 
drug 
HA H+ + A 
Aqueous 
Donor 
Phase 
~ iso . 600 µ I 
.j:::.. 
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TABLE B 
Apparent Partition Coefficients, Dissociation Constants 
and Transport Constants for Six Barbituratesa 
Dissociation Apparent Transport 
Constant Partition Rate Constante 
(.E_Ka) Coefficientb (min-ll 
Barbital 7.86 0.00 0.037 
Phenobarbital 7.37 0.21 0.116 
Butabarbital 8.01 0.07 0.188 
Pentobarbital 8.03 0.50 0.401 
Amobarbital 7.87 0.36 0.662 
Secobarb ital 7.90 0.83 0.727 
aFrom Chiang et al. (1978). 
bObtained from equilibrium partitioning experiments of the 
drugs between liquid membranes with no internal trapping 
agents and the aqueous donor phase. 
cObtained from first order plots with least squares fitting 
program. 
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